Sai Parenterals quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Year before	Change
Revenue	179	—	—
EBITDA	23.5	—	—
EBITDA margin	13.2%	—	—
Profit before tax	9.8	—	—
Net profit	7.9	—	—
EPS	₹1.79	—	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025

Expenses
	179	198	96.2
	3.7	2.9	3.1
	182	201	99.3
	116	114	58.7
	−9.9	10.2	2.6
	11.5	12.2	10.2
	9.4	8.4	5.4
	8.1	8.2	5.8
	37.4	35.3	28.2
	173	188	111
	23.5	26.1	−3.6
	15.4	17.9	−9.3
Profit
	9.8	12.4	−11.6
	9.8	12.4	−11.6
	4.2	1.2	0.6
	−2.3	−1.9	−5.6
	1.9	−0.8	−5.0
	7.9	13.2	−6.7
	7.9	13.2	−6.7
	0.0	0.0	0.0
	7.9	13.2	−6.7
Per share
	₹1.79	₹4.02	−₹2.22
	₹1.79	₹4.02	−₹2.22
Other comprehensive income — detail
	—	0.0	0.0
	—	0.0	0.0
	7.9	—	—
Per share — as-filed variants
	₹1.79	₹4.02	−₹2.22
	₹1.79	₹4.02	−₹2.22
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	72.4	73.6	34.8
	40.5%	37.2%	36.2%
Adjusted (ex-exceptional items) — derived
	9.8	12.4	−11.6
	7.9	13.2	−6.7
	₹1.79	₹4.02	−₹2.22

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SAIPARENT₹484.05

Sai Parenterals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersINDOCO PANACEABIO HIKAL WINDLAS HESTERBIO DCAL SYNCOMF SOLARAMcap ₹2,139 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	96.2	197.9	178.7
Other Income	3.1	2.9	3.7
Total Income	99.3	200.8	182.4
Expenses
+ Cost of Materials Consumed	58.7	114.1	116.1
+ Changes in Inventories	2.6	10.2	-9.9
+ Employee Benefit Expense	10.2	12.2	11.5
+ Finance Costs	5.4	8.4	9.4
+ Depreciation & Amortisation	5.8	8.2	8.1
+ Other Expenses	28.2	35.3	37.4
Total Expenses	110.9	188.4	172.6
EBITDA	-3.6	26.1	23.5
EBIT	-9.3	17.9	15.4
Profit
PBT before Exceptional Items	-11.6	12.4	9.8
Pretax Income	-11.6	12.4	9.8
+ Current Tax	0.6	1.2	4.2
+ Deferred Tax	-5.6	-1.9	-2.3
Tax Expense	-5.0	-0.8	1.9
Net Income	-6.7	13.2	7.9
+ Net Income — Continuing Ops	-6.7	13.2	7.9
+ Other Comprehensive Income	0.0	0.0	0.0
Total Comprehensive Income	-6.7	13.2	7.9
Per Share
Basic EPS	-2.22	4.02	1.79
Diluted EPS	-2.22	4.02	1.79
Other Comprehensive Income — detail
+ Other Comprehensive Income	0.0	0.0	—
+ Items NOT to be Reclassified to P&L	0.0	0.0	—
Comprehensive Income — Owners of Parent	—	—	7.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	-2.22	4.02	1.79
Diluted EPS — Continuing Operations	-2.22	4.02	1.79
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	34.8	73.6	72.4
Gross Margin %	36.23	37.20	40.55
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-11.6	12.4	9.8
Net Income Adj (tax-effected)	-6.7	13.2	7.9
EPS Adj	-2.22	4.02	1.79
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00
Paid Up Equity Capital	18.5	22.1	22.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Sai Parenterals Q2 FY27 results date

Sai Parenterals (NSE: SAIPARENT) will announce its Q2 FY27 results (July–September 2026) on Sunday, 1 November 2026, according to the board-meeting notice it filed on 27 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹7.9 crore, down 39.8% from ₹13.2 crore in Q4 FY26. Revenue from operations was ₹179 crore, down 9.7% from the previous quarter.

Board-meeting notice filed: 27 October 2026
Q1 FY27 results (the latest): 11 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 1 November 2026Sunday · notice filed 27 Oct
Q1 FY27 net profit: ₹7.9 Cr−39.8% vs Q4 FY26
Q1 FY27 revenue: ₹179 Cr−9.7% vs Q4 FY26
Q1 FY27 operating margin: 8.6%−0.4 pts vs Q4 FY26
Q1 FY27 EPS (basic): ₹1.79

Questions

When will Sai Parenterals announce its Q2 FY27 results?

On 1 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 27 October 2026).

What were Sai Parenterals' Q1 FY27 results?

Consolidated net profit was ₹7.9 crore, down 39.8% from ₹13.2 crore in Q4 FY26. Revenue from operations was ₹179 crore, down 9.7% from the previous quarter.

What was Sai Parenterals' net profit in FY26?

Consolidated net profit was ₹14.3 crore in FY26 (April 2025–March 2026).

What was Sai Parenterals' revenue in FY26?

Revenue from operations was ₹381 crore in FY26 (April 2025–March 2026).

Where do these Sai Parenterals figures come from?

From Sai Parenterals' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.